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Abstract
Background and objectives The calcimimetic cinacalcet reduced the risk of death or cardiovascular (CV) events in
older, but not younger, patients with moderate to severe secondary hyperparathyroidism (HPT) who were
receiving hemodialysis. To determine whether the lower risk in younger patients might be due to lower baseline
CV risk and more frequent use of cointerventions that reduce parathyroid hormone (kidney transplantation,
parathyroidectomy, and commercial cinacalcet use), this study examined the effects of cinacalcet in older ($65
years, n=1005) and younger (,65 years, n=2878) patients.
Design, setting, participants, & measurements Evaluation of Cinacalcet HCl Therapy to Lower Cardiovascular
Events (EVOLVE) was a global, multicenter, randomized placebo-controlled trial in 3883 prevalent patients on
hemodialysis, whose outcomes included death, major CV events, and development of severe unremitting HPT.
The age subgroup analysis was prespecified.
ResultsOlder patients had higher baseline prevalence of diabetesmellitus andCV comorbidity. Annualized rates
of kidney transplantation and parathyroidectomy were.3-fold higher in younger relative to older patients and
were more frequent in patients randomized to placebo. In older patients, the adjusted relative hazard (95%
confidence interval) for the primary composite (CV) end point (cinacalcet versus placebo) was 0.70 (0.60 to 0.81);
in younger patients, the relative hazard was 0.97 (0.86 to 1.09). Corresponding adjusted relative hazards for
mortality were 0.68 (0.51 to 0.81) and 0.99 (0.86 to 1.13). Reduction in the risk of severe unremitting HPT was
similar in both groups.
Conclusions In the EVOLVE trial, cinacalcet decreased the risk of death and of major CV events in older, but not
younger, patients with moderate to severe HPT who were receiving hemodialysis. Effect modification by age
may be partly explained by differences in underlying CV risk and differential application of cointerventions that
reduce parathyroid hormone.
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Introduction
Cardiovascular (CV) events occur frequently in patients
with CKD (1). Age-adjusted rates of CV death in pa-
tients with ESRD are $10 times higher than in the gen-
eral population (2). The cause of cardiovascular disease
(CVD) in CKD is multifactorial, but mineral and bone
disorder (MBD), including secondary hyperparathy-
roidism (sHPT), hyperphosphatemia, and vascular cal-
cification, have been implicated (3). Arterial medial
calcification is associated with arteriosclerosis, in-
creased pulse wave velocity, left ventricular hypertro-
phy, diastolic dysfunction, and ultimately heart failure
(4). Arterial intimal calcification advances with the pro-
gression of atherosclerosis and may predispose to ath-
erosclerotic events, including myocardial infarction,
angina, stroke, and peripheral vascular disease (5).
The calcimimetic cinacalcet (Sensipar/Mimpara;
Amgen) modulates the activity of the calcium-sensing
receptor in parathyroid tissue (6) and reduces serum
concentrations of parathyroid hormone (PTH) (7). In
addition, calcimimetic-induced upregulation of the
calcium-sensing receptor in vascular smooth muscle
and endothelial cells may attenuate the progression
of vascular calcification (8–10). In patients receiving
hemodialysis, cinacalcet may slow the progression of
vascular and cardiac-valve calcification (11).
The efficacy of cinacalcet in the prevention of CV
events was examined in the Evaluation of Cinacalcet
HCl Therapy to Lower Cardiovascular Events (EVOLVE)
trial, a global randomized controlled trial (RCT) in
which 3883 patients with moderate to severe sHPTwho
were receiving hemodialysis were randomly assigned
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to either cinacalcet or placebo, in addition to conventional
therapy, which included phosphate binders and vitamin D
sterols in most patients (12). The unadjusted relative hazard
(cinacalcet versus placebo) for the primary composite out-
come (time to death for any cause or major CV events) was
not statistically significant, although the relative hazard ad-
justed for baseline covariates was nominally statistically sig-
nificant (0.88; 95% confidence interval [95% CI], 0.79 to 0.97).
Patients randomized to cinacalcet also experienced lower
rates of parathyroidectomy (PTX) and the composite out-
come of severe unremitting hyperparathyroidism (HPT) (se-
vere HPT with hypercalcemia or PTX) (12,13).
In a prespecified subgroup analysis, the effect of cinacalcet
on the primary outcome was more pronounced in older pa-
tients. The treatment3age (continuous) interaction was signif-
icant (P=0.03) (12). We hypothesized that lower risks of death
and CVD in younger patients and more frequent use of co-
interventions that reduce PTH, including kidney transplanta-
tion and PTX, might explain the observed findings.
Materials and Methods
Study Setting
EVOLVE was a global, multicenter, randomized placebo-
controlled trial of cinacalcet, during which enrolled patients
received conventional therapy for sHPT. Between August
2006 and January 2008, 3883 adult patients on hemodialysis
were enrolled from 5755 individuals who were screened.
Patients were followed for up to 64 months. The trial design
and procedures (14), baseline characteristics of trial partici-
pants (15), inclusion/exclusion criteria, Consolidated Standards
of Reporting Trials diagram, sample size estimate, results of
the primary composite and the secondary end points, and
adverse event rates were previously reported (12).
The EVOLVE trial was sponsored by Amgen Inc. An
academically led executive committee supervised the trial
design and operations. An independent data monitoring
committee reviewed safety data and interim analyses for
efficacy. All primary and secondary end points were adjudi-
cated by an independent clinical events classification group.
The study was approved by institutional review boards at
participating study sites and the authors adhered to the Dec-
laration of Helsinki in the conduct of this trial (ClinicalTrials.
gov NCT00345839).
Study Population
Eligible participants received hemodialysis three times per
week with plasma PTH concentrations $300 pg/ml (31.8
pmol/L), serum calcium phosphate product $45 mg2/dl2
(3.63 mmol2/L2), and serum calcium $8.4 mg/dl (2.1
mmol/L). Written informed consent was obtained from all
patients.
Study Design
Randomization. Randomization was stratified by coun-
try and diabetes status using fixed blocks. Treatment assign-
ment was blinded to investigators, trial participants, and the
sponsor.
Subgroup Analyses. To determine treatment effect modi-
fiers, the following seven factors were prespecified for
subgroup analysis: age (,65 and $65 years), sex, race, geo-
graphic region, baseline plasma PTH, and baseline use of
vitamin D. Only age was associated with a significant treat-
ment interaction (12).
Biochemical Determinations. Biochemical markers of
CKD-MBD were measured throughout the trial, including
plasma PTH and serum concentrations of total calcium,
phosphorus, total alkaline phosphatases, and bone-specific
alkaline phosphatase. All determinations were done in central
laboratories using established methods (15).
Outcomes. The primary composite end point was the
time to death of any cause or the first nonfatal CV event
(myocardial infarction, hospitalization for unstable angina,
heart failure, or peripheral vascular disease). Detailed defi-
nitions are provided in Supplemental Table 1. Outcomes
associated with the progression of HPT included PTX and
development of severe unremitting HPT.
There were no protocol-specified criteria, either biochemical
or otherwise, that prompted surgical PTX. We defined severe
unremitting HPT as time to the first occurrence of any of the
three following events: (1) plasma PTH .1000 pg/ml with
serum total calcium .10.5 mg/dl (2.6 mmol/L) on two con-
secutive occasions, or (2) plasma PTH .1000 pg/ml and se-
rum total calcium.10.5 mg/L (2.6 mmol/L) on one occasion
with prescription of commercial cinacalcet within 2 months,
or (3) surgical PTX (13).
Statistical Analyses
All end point data were collected and analyzed using the
intention-to-treat principle. The following analyses were
performed for prespecified age categories of$65 years and
,65 years. Kaplan–Meier product-limit estimates of the
event-free survival time were computed and compared
between treatment groups using a two-sided log-rank
test stratified by country and history of diabetes mellitus
(yes/no). The relative hazard (cinacalcet versus placebo)
and 95% CIs were calculated using Cox proportional-hazards
regression models, also stratified according to country
and history of diabetes mellitus. We conducted multivari-
able analyses in which we adjusted for baseline covariates
using a stepwise selection procedure. For the primary
composite end point, we conducted prespecified compan-
ion analyses in which data were censored at the time of
kidney transplantation, PTX, or off-protocol initiation of
commercial cinacalcet, alone or in combination. The pri-
mary analysis (unadjusted log-rank test) did not reach
statistical significance (12). The analyses presented
herein are not adjusted for multiplicity and P values
,0.05 are considered nominally significant. Data on ad-
verse events were collected while patients were taking
the study drug (12). Statistical analyses were performed
using SAS software (version 9.2; SAS Institute Inc, Cary,
NC).
Results
Baseline Characteristics
There were 2878 (74%) patients aged ,65 years and 1005
(26%) aged $65 years (Table 1). The prevalence of white
race, diabetes mellitus, and CVD (including heart failure,
peripheral vascular disease, coronary artery revasculariza-
tion, myocardial infarction, stroke, and atrial fibrillation)
was higher in older patients, as was the use of vitamin D
sterols, antiplatelet agents, and statins.
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Exposure and Adherence
In patients randomized to cinacalcet, duration of exposure
(median 16 months; 10th and 90th percentile range, 2–49
months) and median daily dose (46 mg; 10th and 90th per-
centile range, 26–109 mg) were lower in older patients (23
months; 10th and 90th percentile range, 2–52 months) relative
to younger patients (58 mg; 10th and 90th percentile range,
29–136 mg) (Supplemental Table 2). In patients randomized
to placebo, the maximum dose level was reached in 76% of
older patients and 81% of younger patients. Reasons for dis-
continuation are provided in Supplemental Table 3.
Biochemical Markers of and Concomitant Medications for
CKD-MBD
Baseline biochemical markers by age group are provided
in Table 1. The absolute reduction in PTH after use of cina-
calcet was similar in both age groups and was sustained
over time. Baseline use of vitamin D sterols and phosphate
binders by treatment group (stratified by age) is provided in
Supplemental Table 4.
Use of Kidney Transplantation, PTX, and Commercial
Cinacalcet in the Placebo Group
Among patients randomized to placebo, exposure to severe
HPT was limited by cointerventions to a greater extent in
younger patients. The annualized transplantation rate (per-
centage per year) was 2.0 (95% CI, 1.3 to 2.9) in older patients
and 7.1 (95%CI, 6.4 to 7.9) in younger patients. By year 3, 6.2%
of older patients had been transplanted comparedwith 20% of
younger patients (Figure 1A).
Corresponding annualized PTX rates were 1.7 (95% CI,
1.1 to 2.6) and 5.2 (95% CI, 4.6 to 5.8). By year 3, 3.7% of
older patients had PTX compared with 15.6% of younger
patients (Figure 1B). The annualized rates of commercial
cinacalcet use were similar in both age groups (Figure 1C).
By year 3, 32% of older patients had received one or more
of these cointerventions compared with 50% of younger
patients.
The Effects of Cinacalcet
Primary End Point. The effect of cinacalcet on the pri-
mary composite end point was more pronounced in patients
aged $65 years, compared with patients aged ,65 years
(P=0.01) (Figure 2A). In older patients, the relative hazard
adjusted for baseline covariates (cinacalcet versus placebo)
for the primary composite end point was 0.70 (95% CI, 0.60
to 0.81); in younger patients, the relative hazard was 0.97
(95% CI, 0.86 to 1.09). The relative hazard by decade is pro-
vided in Figure 3. Annualized event rates and relative haz-
ards for components of the primary composite end point are
shown in Table 2. Event rates were substantially higher in
older patients. The differential treatment effect by age was
observed for mortality, myocardial infarction, and peripheral
vascular disease, but not for unstable angina.
Mortality. The adjusted relative hazard for all-cause mor-
tality in older patients was 0.68 (95% CI, 0.58 to 0.81); in
younger patients, the relative hazard was 0.99 (95% CI,
0.86 to 1.13) (Figure 2B).
Severe Unremitting HPT. Few parathyroidectomies were
undertaken in older patients (Figure 1B); the effect of cinacal-
cet on abrogating the provision of PTX was evident only in
the younger patients. When we considered the composite
outcome of severe unremitting HPT, rates were higher in
younger patients, although the effect of cinacalcet was similar
in older (relative hazard, 0.46; 95% CI, 0.31 to 0.69) and youn-
ger patients (0.43; 95% CI, 0.36 to 0.51) (Figure 2C).
Analyses with Censoring by PTH-Lowering Events
When we censored data for patients after kidney trans-
plantation, the relative hazard for the primary composite end
point was 0.74 (95% CI, 0.63 to 0.86) in older patients and 0.95
(95% CI, 0.84 to 1.07) in younger patients. When censoring
data after PTX, corresponding results were 0.72 (95% CI, 0.62
to 0.84) and 0.97 (95% CI, 0.87 to 1.10). When censoring data
after the start of commercial cinacalcet, corresponding results
were 0.70 (95% CI, 0.60 to 0.83) and 0.97 (95% CI, 0.85 to 1.09).
Censoring at the time of any of these three events—all of
which would be expected to correct or treat sHPT—
yielded a relative hazard of 0.70 (95% CI, 0.59 to 0.82) in older
patients and 0.89 (95% CI, 0.78 to 1.02) in younger patients.
Side Effects
In patients randomized to cinacalcet, exposure-adjusted
rates of nausea, vomiting, and hypocalcemia were similar
across age groups (Supplemental Table 5).
Discussion
In the EVOLVE trial, we previously showed a nominally
statistically significant benefit of cinacalcet on the primary
composite end point in older compared with younger pa-
tients with moderate to severe sHPT who were receiving
hemodialysis (12). Here we show that all-cause mortality
was also significantly reduced in the older patients. The an-
nualized mortality rate was 20.4% in patients randomized to
placebo and 15.9% in patients randomized to cinacalcet. Be-
cause older and younger patients on hemodialysis differ in
many ways, we aimed to explore these differences in detail.
The absence of a treatment effect in younger patients con-
trasts with the 30% reduction in the risk of the primary com-
posite end point and the 32% reduction in the risk of death
in older patients. This effect modification by age can be ex-
plained by one of several factors, such as a true difference in
the treatment effect, bias introduced by differential applica-
tion of cointerventions (including kidney transplantation,
PTX, and provision of commercial cinacalcet), differential
susceptibility to the effects of sHPT for which cinacalcet is
prescribed, or lower event rates in younger patients, thereby
reducing statistical power. Very high rates of discontinua-
tion of the study drug were known to have lowered the
trial’s power well below what had been anticipated (12).
Our results demonstrate differential application of PTH-
lowering interventions, with kidney transplantation and PTX
performed .3 times more frequently in younger patients.
Analyses in which we accounted for PTH-lowering therapies
failed to show a significant benefit in younger patients, al-
though the 95% CIs of the relative hazards were more
closely aligned with those observed in older patients. Youn-
ger patients had substantially less CV comorbidity than
older patients at baseline, and diminished CV risk was con-
firmed by the markedly lower CV event rates experienced
during the trial in this age group.
The effect of alterations in mineral metabolism induced
by cinacalcet on calcification of either intimal or medial
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Table 1. Baseline characteristics by age group and by treatment arm
Characteristic
Age ,65 yr (n=2878) Age $65 yr (n=1005)
Cinacalcet
(N1=1418)
Placebo
(N1=1460)
Cinacalcet
(N1=530)
Placebo
(N1=475)
Age (yr)a 50 (32, 61) 50 (33, 61) 71 (66, 80) 71 (66, 80)
Womenb 569 (40) 574 (39) 240 (45) 195 (41)
Race or ethnic groupa
White 771 (54) 785 (54) 353 (67) 331 (70)
Black 321 (23) 341 (23) 88 (17) 87 (18)
Other 326 (23) 334 (23) 89 (17) 57 (12)
Regiona
United States 520 (37) 534 (37) 195 (37) 181 (38)
Europe 387 (27) 407 (28) 211 (40) 183 (39)
Latin America 292 (21) 302 (21) 53 (10) 40 (8)
Russia 128 (9) 126 (9) 15 (3) 14 (3)
Australia 43 (3) 45 (3) 31 (6) 30 (6)
Canada 48 (3) 46 (3) 25 (5) 27 (6)
Dialysis vintage (mo)a 47 (9, 156) 48 (11, 159) 40 (7, 106) 39 (9, 116)
Current dialysis accessa
Fistula 1062 (75) 1073 (74) 363 (69) 317 (67)
Graft 172 (12) 205 (14) 75 (14) 78 (16)
Permanent catheter 151 (11) 155 (11) 80 (15) 67 (14)
Other 33 (2) 27 (2) 12 (2) 13 (3)
BP (mmHg)
Systolic 140 (111, 177) 140 (111, 178) 140 (110, 175) 141 (111, 175)
Diastolica 80 (60, 100) 80 (63, 100) 72 (56, 89) 73 (60, 89)
Tobacco usea
Never 774 (55) 829 (57) 312 (59) 269 (57)
Current 279 (20) 289 (20) 33 (6) 31 (7)
Former 363 (26) 341 (23) 185 (35) 175 (37)
Diabetesa 414 (29) 422 (29) 240 (45) 226 (48)
Heart failurea 281 (20) 294 (20) 169 (32) 162 (34)
Peripheral vascular diseasea 181 (13) 194 (13) 132 (25) 128 (27)
Coronary artery bypass grafta 58 (4) 68 (5) 77 (15) 86 (18)
Percutaneous coronary
interventiona
79 (6) 81 (6) 51 (10) 51 (11)
Myocardial infarctiona 138 (10) 132 (9) 101 (19) 112 (24)
Strokea 99 (7) 132 (9) 63 (12) 61 (13)
Transient ischemic attacka 54 (4) 40 (3) 46 (9) 34 (7)
Amputation 86 (6) 89 (6) 35 (7) 40 (8)
Atrial fibrillationa 82 (6) 109 (8) 120 (23) 116 (24)
Parathyroidectomyc 79 (6) 71 (5) 12 (2) 16 (3)
Fracture 265 (19) 292 (20) 117 (22) 95 (20)
iPTH (pg/ml)a 732 (373, 1756) 747 (379, 1799) 608 (338, 1565) 580 (322, 1316)
Corrected serum calcium
(mg/dl)a
9.7 (9.0, 10.7) 9.8 (9.0, 10.7) 9.9 (9.1, 10.8) 9.9 (9.1, 10.8)
Serum phosphorus (mg/dl)a 6.4 (5.1, 8.5) 6.4 (5.0, 8.6) 5.9 (4.8, 7.8) 5.7 (4.7, 7.7)b
Serum total alkaline
phosphatases (mg/L)a
111 (66, 259) 110 (65, 246) 98 (63, 214) 105 (65, 193)
Serum bone alkaline phosphatases
$21 (mg/L)a
820 (58) 811 (56) 247 (47) 232 (49)
Serum albumin (g/dl)a 3.7 (3.2, 4.1) 3.7 (3.2, 4.1) 3.6 (3.1, 4.0) 3.6 (3.1, 4.0)
Medication use 821 (56) 832 (57) 335 (63) 322 (68)
Vitamin D sterola 770 (54) 795 (55) 267 (50) 230 (48)
Calcium-containing phosphate
binderc
484 (34) 514 (35) 190 (36) 183 (39)
Noncalcium-containing phosphate
binder
b-adrenergic antagonists 690 (49) 669 (46) 255 (48) 209 (44)
RAS inhibitors 651 (46) 633 (43) 222 (42) 194 (41)
Antiplatelet agentsa 455 (32) 489 (34) 279 (53) 247 (52)
Statinsa 395 (28) 400 (27) 252 (48) 214 (45)
Data are presented as the median (10th and 90th percentiles) or n (%) unless otherwise indicated. Percentages are based on N1. Sig-
nificance of the differences between each age group, combining those randomized to placebo and to cinacalcet, are indicated by lettered
footnotes. iPTH, intact parathyroid hormone; RAS, renin-angiotensin system.
aP value ,0.001.
bP value ,0.05.
cP value ,0.01.
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lesions may be diminished in younger patients. Advanced
age and diabetes mellitus are consistent risk factors for the
presence and progression of coronary artery calcifications
(16). Medial thickness and calcification are increased in pa-
tients with ESRD (17,18). Using mammograms to assess
breast arterial calcification (a marker of generalized medial
artery calcification) in patients with CKD, age and eGFR
were independent predictors of the presence and severity
of medial arterial calcification (19). In patients on hemodial-
ysis with high calcification scores compared with those with
little or no calcification, age and diabetes were two of
three independent predictors of severe calcification (20).
It seems reasonable to suggest that younger patients in
EVOLVE, in whom diabetes mellitus was present less fre-
quently, had less baseline atherosclerotic disease and less
arteriosclerosis than older patients, and were thus less
susceptible to the beneficial effect of cinacalcet. In addi-
tion, there is a link between demineralization of bone and
the presence of vascular calcification (21). Because both of
these processes are associated with older age, this link
Figure 1. | Kaplan-Meier time-to-event curves for cointerventions that reduce parathyroid hormone (PTH). Time to kidney transplantation
(A), parathyroidectomy (B), and use of commercial cinacalcet (C) in the groups randomized to placebo (dotted line, ,65 years; dashed line,
$65 years) and to cinacalcet (solid line, ,65 years; bold line, $65 years) by age group.
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may explain the more pronounced effect of cinacalcet in
older patients.
There are several strengths to the analyses presented here.
Our results are derived from a relatively large global RCT,
with end points adjudicated by a blinded clinical events
committee, with low drop-out rates and very little missing
outcome data. Although we focused on a subgroup analysis,
older versus younger age was one of only seven prespecified
subgroups. The analyses presented consider only an intention-
to-treat approach, the most conservative of all analytic ap-
proaches, because it assesses the effect of randomization to
treatment and takes no account of nonadherence to study
drug. Using methods to account for nonadherence, the
estimated effects of cinacalcet were more pronounced (12). In
subgroup analyses, differences in baseline characteristics
between the intervention and control groups are more likely
to vary by chance but we focused on treatment effects ad-
justed for baseline covariates. Clearly, the statistical power of
the EVOLVE trial to detect treatment differences in the youn-
ger patients was low due to the small number of events.
Ten criteria associated with design, analysis, and context
have been proposed to assess the credibility of a subgroup
effect in RCTs (22). The age treatment effect in the EVOLVE
trial met most of these criteria: (1) age $65 and ,65 years
Figure 2. | Kaplan-Meier time-to-event curves for clinical end points. Time to the primary composite cardiovascular end point (A), to death (B),
and to severe unremitting hyperparathyroidism (C) in the groups randomized to placebo (dotted line,,65 years; dashed line,$65 years) and to
cinacalcet (solid line, ,65 years; bold line, $65 years) by age group.
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was a baseline characteristic, although (2) the subgroup was
not a stratification factor at randomization; (3) the age sub-
group analysis was prespecified before the start of the trial,
and (4) was one of a small number (n=7) of prespecified
subgroup hypotheses tested; (5) the test of treatment3age
interaction was significant; (6) the age3interaction effect was
significant and independent of other significant interactions;
(7) the direction of the age subgroup effect was not prespe-
cified; (8) the age subgroup effect is consistent with that
reported for the phosphate binder sevelamer, compared
with calcium-based phosphate binders on mortality in
2103 patients receiving hemodialysis (23); (9) the age sub-
group effect was consistent across related outcomes (all-
cause mortality, myocardial infarction, and peripheral
vascular disease, but not unstable angina); and (10) the
biologic rationale for the age subgroup effect (lower base-
line CV risk and higher use of cointerventions that lower
PTH in younger patients) is logical. We suggest that the
cinacalcet effect modification by age is credible, but an-
other trial of calcimimetics would be beneficial for inform-
ing clinical practice.
Cinacalcet decreased the risk of death and of major CV
events in older, but not younger, patients with moderate to
severe sHPT who were receiving hemodialysis. Cinacalcet
reduced the risk of severe unremitting HPT in all patients.
CV effect modification by age may be partly explained by
differences in baseline CV risk and by differential appli-
cation of cointerventions that reduce PTH. Clinicians will
need to balance the potential benefits of cinacalcet on the
CKD-associated CVD and MBD with its known adverse
Figure 3. | Unadjusted relative hazards (6 95% confidence intervals) by decade for the primary composite end point (cinacalcet versus
placebo) using intention-to-treat analysis.
Table 2. Annualized event rates and hazard ratios for cardiovascular end points and mortality by age group
End Point
Age ,65 yr (n=2878) Age $65 yr (n=1005)
Annual Event Rate
Relative
Hazard
Annual Event Rate
Relative
HazardPlacebo
(N1=1460)
Cinacalcet
(N1=1418)
Placebo
(N1=475)
Cinacalcet
(N1=530)
Primary
composite
CVD
11.4
(10.6 to 12.3)
11.3
(10.5 to 12.2)
0.99
(0.88 to 1.11)
28.3
(25.9 to 30.9)
22.6
(20.5 to 24.7)
0.74
(0.63 to 0.86)
All-cause
mortality
7.0
(6.4 to 7.7)
7.1
(6.5 to 7.8)
1.01
(0.88 to 1.16)
20.4
(18.4 to 22.5)
15.9
(14.3 to 17.7)
0.73
(0.62 to 0.86)
Myocardial
infarction
1.9
(1.6 to 2.3)
2.4
(2.0 to 2.8)
1.2
(0.92 to 1.57)
6.3
(5.0 to 7.8)
4.0
(3.1 to 5.0)
0.60
(0.43 to 0.85)
Unstable
angina
0.9
(0.7 to 1.2)
0.6
(0.4 to 0.9)
0.66
(0.43 to 1.03)
1.2
(0.7 to 2.0)
1.4
(0.9 to 2.1)
1.19
(0.62 to 2.29)
Heart failure 2.9
(2.5 to 3.4)
2.5
(2.1 to 2.9)
0.82
(0.64 to 1.03)
6.6
(5.3 to 8.1)
4.8
(3.8 to 6.0)
0.76
(0.56 to 1.05)
Peripheral
vascular
disease
2.3
(1.9 to 2.7)
2.2
(1.8 to 2.7)
0.99
(0.76 to 1.28)
6.3
(5.0 to 7.8)
4.2
(4.2 to 5.3)
0.69
(0.49 to 0.96)
Data are presented with 95% confidence intervals. CVD, cardiovascular disease.
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effects, including nausea, vomiting, and hypocalcemia,
when determining the optimal approach to the treatment of
sHPT in all patients on dialysis.
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